Heidi Drummer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2414741/publications.pdf

Version: 2024-02-01

28	1,203	14	27
papers	citations	h-index	g-index
30	30	30	2238
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. Journal of Virology, 2022, 96, JVI0167521.	1.5	8
2	A panâ€genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice. Hepatology, 2022, 76, 1190-1202.	3.6	12
3	To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses, 2021, 13, 805.	1.5	4
4	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	5. 6	244
5	10th Lorne Infection and Immunity Conference 2020. Immunology and Cell Biology, 2020, 98, 805-806.	1.0	O
6	Infectious KoRV-related retroviruses circulating in Australian bats. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9529-9536.	3.3	31
7	Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine. Journal of Biological Chemistry, 2020, 295, 7179-7192.	1.6	21
8	Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. Journal of Virology, 2018, 92, .	1.5	20
9	A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81. Wellcome Open Research, 2017, 2, 82.	0.9	16
10	Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection. PLoS ONE, 2015, 10, e0126397.	1.1	6
11	Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Frontiers in Microbiology, 2014, 5, 329.	1.5	62
12	Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity. PLoS Pathogens, 2013, 9, e1003218.	2.1	12
13	High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study. PLoS ONE, 2013, 8, e80216.	1.1	53
14	<i>In silico</i> directed mutagenesis identifies the <scp>CD</scp> 81/claudinâ€1 hepatitis <scp>C</scp> virus receptor interface. Cellular Microbiology, 2012, 14, 1892-1903.	1.1	35
15	Claudin Association with CD81 Defines Hepatitis C Virus Entry. Journal of Biological Chemistry, 2010, 285, 21092-21102.	1.6	182
16	The SR-BI Partner PDZK1 Facilitates Hepatitis C Virus Entry. PLoS Pathogens, 2010, 6, e1001130.	2.1	48
17	Role for the disulfide-bonded region of human immunodeficiency virus type $1\mathrm{gp41}$ in receptor-triggered activation of membrane fusion function. Biochemical and Biophysical Research Communications, 2010, 394, 904-908.	1.0	11
18	Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix. Journal of Virological Methods, 2009, 158, 35-40.	1.0	7

#	Article	IF	CITATIONS
19	T CD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. Immunology and Cell Biology, 2009, 87, 464-472.	1.0	10
20	High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology, 2008, 48, 1746-1752.	3.6	115
21	An N-terminal glycine-rich sequence contributes to retrovirus trimer of hairpins stability. Biochemical and Biophysical Research Communications, 2007, 359, 1037-1043.	1.0	4
22	Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin. Journal of Clinical Virology, 2007, 39, 288-294.	1.6	12
23	A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology, 2007, 45, 911-920.	3.6	26
24	Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and Tâ€helper epitopes. Immunology and Cell Biology, 2007, 85, 169-173.	1.0	16
25	Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2. Biochemical and Biophysical Research Communications, 2005, 328, 251-257.	1.0	46
26	Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core. FEBS Letters, 2004, 567, 183-188.	1.3	13
27	Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Letters, 2003, 546, 385-390.	1.3	175
28	A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus. Electrophoresis, 1993, 14, 926-936.	1.3	5